Preserving Muscle on GLP-1 Medications: What Research Recommends

GLP-1 medications are remarkably effective at producing rapid weight loss, but rapid weight loss always carries a trade-off. Some portion of weight lost during any caloric deficit comes from lean tissue, including muscle mass, rather than fat alone.

Understanding this dynamic and taking proactive steps to preserve muscle while losing fat is one of the most important things you can do to protect your metabolism and long-term health outcomes.

What Clinical Trials Show About Body Composition

The STEP 1 trial (the pivotal Phase 3 trial of semaglutide 2.4 mg) achieved an average 14.9% weight loss over 68 weeks. While the trial did not report detailed body composition data as a primary endpoint, subsequent research and sub-analyses have raised an important question: what proportion of that weight loss was fat versus lean tissue?

Studies using DEXA (dual-energy X-ray absorptiometry) scans during GLP-1 therapy have found that approximately 25-40% of total weight lost on GLP-1 medications may be lean mass (including muscle, bone, and water) with the remainder being fat mass. This is broadly consistent with weight loss ratios observed in other caloric-restriction approaches, but the rapidity of loss on GLP-1 therapy may amplify the muscle loss concern.

A 2017 review in *Advances in Nutrition* by Cava and colleagues on preserving muscle during weight loss found that the key determinants of lean mass preservation are adequate protein intake and resistance exercise, both of which require intentional effort during GLP-1 therapy given the significant appetite suppression these medications produce.

Why Muscle Loss Matters

Muscle tissue is metabolically expensive; it burns more calories at rest than fat tissue. Losing substantial muscle during weight loss means:

• Lower resting metabolic rate: Less muscle means fewer calories burned at rest, making weight maintenance harder after treatment
• Reduced functional capacity: Muscle loss affects strength, mobility, and quality of life, particularly important as we age
• Sarcopenic obesity risk: A state of low muscle mass with elevated body fat, associated with metabolic dysfunction and increased mortality risk

Preserving muscle during weight loss sets a better foundation for long-term metabolic health, independent of the scale number.

Evidence-Based Strategies for Muscle Preservation

Protein Intake: The Primary Lever

The most powerful tool for preserving lean mass during weight loss is adequate protein intake. Research consistently shows that higher protein diets during caloric restriction produce better lean mass outcomes.

On GLP-1 therapy, the challenge is that appetite suppression dramatically reduces total food consumption. If protein intake falls proportionally with caloric intake, muscle loss accelerates.

Evidence-based targets during GLP-1 therapy:

• Minimum: 1.2 grams of protein per kilogram of body weight per day
• Optimal: 1.6 grams per kilogram per day
• For those with significant obesity: some researchers recommend calculating based on goal weight rather than current weight

High-quality protein sources (poultry, fish, eggs, dairy, legumes) should be prioritized at every meal. When appetite suppression makes adequate intake from whole foods difficult, protein supplements (whey, casein, or plant-based) can help bridge the gap.

Resistance Training: The Second Pillar

Exercise during GLP-1 therapy is not optional if muscle preservation is a goal. Resistance training provides the mechanical signal that tells the body to maintain and build muscle tissue, a signal that diet alone cannot replicate.

The recommendation is not to do more exercise than you are currently doing. It is to ensure that some of your exercise includes resistance work: weight training, bodyweight exercises, resistance bands, or other forms of loading that challenge muscles against resistance 2-3 times per week.

Aerobic exercise supports cardiovascular health and overall caloric expenditure but is less effective than resistance training for preventing muscle loss during caloric restriction.

Adequate Total Calories (Not Aggressive Restriction)

GLP-1 medications naturally create substantial caloric deficits. Very aggressive caloric restriction (below 1,200 calories per day for most adults) accelerates muscle loss. The appetite suppression of GLP-1 therapy can inadvertently push some individuals into undereating ranges that impair muscle preservation.

Working with a registered dietitian or healthcare provider to ensure caloric intake remains above ~1,400-1,600 calories per day (for most adults) helps create a deficit large enough for meaningful fat loss without accelerating lean tissue catabolism.

Monitoring Body Composition, Not Just Weight

The scale is a blunt instrument that does not distinguish between fat loss and muscle loss. Regular body composition assessment (through DEXA scan, bioelectrical impedance, or regular skinfold measurements) provides far more useful information about whether weight loss is predominantly from fat stores.

The Long-Term Picture

The STEP 4 trial showed that continuing semaglutide therapy maintained weight loss, while stopping led to progressive weight regain. This underscores the importance of building healthy body composition habits during treatment, particularly adequate protein intake and resistance exercise, that can sustain muscle mass and metabolic rate regardless of what happens with the medication over time.

*This article summarizes published research and does not constitute medical advice. Individual body composition goals should be discussed with a qualified healthcare provider. Results may vary.*

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). *N Engl J Med.* 2021 Mar. PMID 33567185. [https://pubmed.ncbi.nlm.nih.gov/33567185/](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). *JAMA.* 2021 Apr. PMID 33755728. [https://pubmed.ncbi.nlm.nih.gov/33755728/](https://pubmed.ncbi.nlm.nih.gov/33755728/)
3. Alawadhi AA, et al. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide use: a randomized trial. *BMJ Open.* 2026 Apr. PMID 42020128. [https://pubmed.ncbi.nlm.nih.gov/42020128/](https://pubmed.ncbi.nlm.nih.gov/42020128/)
4. Mechanick JI, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for obesity treatment in primary care. *Obes Rev.* 2025 Jan. PMID 39295512. [https://pubmed.ncbi.nlm.nih.gov/39295512/](https://pubmed.ncbi.nlm.nih.gov/39295512/)